This study looks at **rocatinlimab**, a medicine being tested to help people with moderate-to-severe asthma. Asthma is a condition where it's hard to breathe because the airways in the lungs get swollen. The study aims to see if rocatinlimab can help reduce asthma attacks, also known as exacerbations.

To participate, you need to be 18-75 years old, have had asthma for over a year, and currently use inhaled steroids with another controller medicine. You should have had at least one asthma attack in the past year.

However, you cannot join if you have other lung diseases, smoke, or have had a recent COVID-19 infection. Also, if you have certain infections, cancers, or HIV, you are not eligible.

• **Study Duration:** Participation will require multiple visits over a period of time.
• **Compensation:** Participants may receive compensation for time and travel.
• **Risks:** As with any study, there may be risks involved, and these will be explained before you agree to join.

Rocatinlimab is still being studied, so it’s important to understand the possible benefits and risks before joining.